- Home
- REGN vs MPLX Comparison
REGN vs MPLX Comparison
Compare REGN & MPLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- MPLX
- Stock Information
- Founded
- REGN 1988
- MPLX 2012
- Country
- REGN United States
- MPLX United States
- Employees
- REGN N/A
- MPLX N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- MPLX Oil & Gas Production
- Sector
- REGN Health Care
- MPLX Energy
- Exchange
- REGN Nasdaq
- MPLX Nasdaq
- Market Cap
- REGN 63.4B
- MPLX 54.7B
- IPO Year
- REGN 1991
- MPLX 2012
- Fundamental
- Price
- REGN $490.28
- MPLX $51.02
- Analyst Decision
- REGN Buy
- MPLX Buy
- Analyst Count
- REGN 23
- MPLX 9
- Target Price
- REGN $891.17
- MPLX $54.33
- AVG Volume (30 Days)
- REGN 1.5M
- MPLX 1.4M
- Earning Date
- REGN 04-29-2025
- MPLX 05-06-2025
- Dividend Yield
- REGN 0.36%
- MPLX 7.50%
- EPS Growth
- REGN 16.49
- MPLX 11.58
- EPS
- REGN 39.43
- MPLX 4.33
- Revenue
- REGN $14,085,700,000.00
- MPLX $11,380,000,000.00
- Revenue This Year
- REGN N/A
- MPLX $16.90
- Revenue Next Year
- REGN $6.97
- MPLX $4.73
- P/E Ratio
- REGN $12.43
- MPLX $11.78
- Revenue Growth
- REGN 7.52
- MPLX 5.46
- 52 Week Low
- REGN $485.00
- MPLX $39.95
- 52 Week High
- REGN $1,211.20
- MPLX $54.87
- Technical
- Relative Strength Index (RSI)
- REGN 32.32
- MPLX 51.08
- Support Level
- REGN $590.15
- MPLX $50.41
- Resistance Level
- REGN $608.17
- MPLX $51.55
- Average True Range (ATR)
- REGN 18.79
- MPLX 0.89
- MACD
- REGN -3.82
- MPLX 0.05
- Stochastic Oscillator
- REGN 3.98
- MPLX 63.11
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About MPLX MPLX LP
MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.